CNSY (Cerenome) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNSY Cerenome Inc CNSY
29 GF Score
Price $2.02
GF Value $0.98
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Cerenome SpecialCharges?

Special Charges only applies to banks.

CNSY
29GF Score
Cerenome Inc CNSY
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cerenome (CNSY) Overvalued in 2026?

Based on GuruFocus' analysis, Cerenome stock appears to be overvalued. The current stock price of $2.02 is trading 106.1% above its estimated GF Value™ of $0.98. GuruFocus considers Cerenome to be Significantly Overvalued.

Key valuation signals for CNSY:

  • SpecialCharges:
  • GF Value™: $0.98 vs. price of $2.02 (106.1% above fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the CNSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cerenome Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
29GF Score

Get the complete analysis for CNSY

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price
$0.98
GF Value